MedPath

Avalyn Pharma Inc.

Avalyn Pharma Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:0

Trial Phases

1 Phases

Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (100.0%)

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Phase 2
Not yet recruiting
Conditions
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
First Posted Date
2025-04-30
Last Posted Date
2025-04-30
Lead Sponsor
Avalyn Pharma Inc.
Target Recruit Count
340
Registration Number
NCT06951217
Locations
🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis

Phase 2
Recruiting
Conditions
Progressive Pulmonary Fibrosis
First Posted Date
2024-08-20
Last Posted Date
2025-05-05
Lead Sponsor
Avalyn Pharma Inc.
Target Recruit Count
141
Registration Number
2023-508429-29-00
Locations
🇩🇪

Muenchen Klinik gGmbH, Munich, Germany

🇩🇪

Universitaet Leipzig, Leipzig, Germany

🇩🇪

Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH, Essen, Germany

and more 38 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.